Status:
COMPLETED
Improving Platelet Activity for Cerebral Hemorrhage Treatment - DDAVP Proof of Concept
Lead Sponsor:
Northwestern University
Collaborating Sponsors:
Northwestern Memorial Hospital
Conditions:
Intracerebral Hemorrhage
Eligibility:
All Genders
18-85 years
Phase:
PHASE2
Brief Summary
The investigators intend to show that DDAVP improves platelet activity from baseline to 60 minutes after treatment start.
Eligibility Criteria
Inclusion
- Spontaneous intracerebral hemorrhage as documented by head CT scan
- Documented regular aspirin use or VerifyNow-ASA result of ≤ 550 aspirin reaction units (ARU), indicating anti-platelet medication
Exclusion
- International normalized ratio (INR) of ≥ 1.7 from coagulopathy or warfarin use
- History of von Willebrand disease
- Pregnancy
- Known hypersensitivity to DDAVP or desmopressin
- Active cardiovascular disease or unstable angina
- Hyponatremia or history of hyponatremia
- Current or historical deep venous thrombosis or pulmonary embolism
Key Trial Info
Start Date :
December 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2013
Estimated Enrollment :
14 Patients enrolled
Trial Details
Trial ID
NCT00961532
Start Date
December 1 2010
End Date
December 1 2013
Last Update
August 28 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Northwestern Memorial Hospital
Chicago, Illinois, United States, 60611